MDMA Assisted Psychotherapy Decreases PTSD Symptoms, Dissociation, Functional Disability, and Depression: A Systematic Review and Meta-Analysis

PTSD is a common and often persistent disorder characterised by intrusive memories, avoidance, negative alterations in cognition and mood, and marked changes in arousal. Population surveys report a 12-month prevalence averaging 1.1% internationally and a lifetime prevalence around 8%, with substantially higher rates in some groups such as combat veterans. Despite evidence-based behavioural therapies (for example, cognitive processing or exposure therapies) and pharmacotherapies (SSRIs and SNRIs), a substantial proportion of patients remain symptomatic or develop chronic, treatment-resistant PTSD, creating a demand for novel treatments. This study set out to synthesise randomised controlled trial evidence on MDMA-assisted psychotherapy (MDMA-AP) for PTSD and its associated outcomes. Building on prior trials sponsored largely by the Multidisciplinary Association for Psychedelic Studies (MAPS) and mechanistic theories that MDMA may enhance cognitive flexibility, memory reactivation/reconsolidation, and fear extinction when combined with psychotherapy, Green and colleagues performed a systematic review and meta-analysis to quantify effects on clinician-rated PTSD severity (CAPS) and a set of secondary outcomes including dissociation, functional impairment, depression, sleep quality and physiological measures.

Green and colleagues conducted a systematic review and meta-analysis of randomised controlled trials comparing MDMA-AP with psychotherapy-alone control conditions. Eligible studies enrolled adults with a PTSD diagnosis and used the Clinician-Administered PTSD Scale (CAPS-IV or CAPS-5) as the primary outcome. Trials were excluded if they were preclinical, animal, non-English, reviews, or enrolled children/adolescents. The search covered MEDLINE, PsycINFO, PsycARTICLES, the Cochrane Library and ClinicalTrials.gov from inception to 8 July 2022, and included trial registries to identify unpublished studies. Two reviewers screened titles and abstracts, with a third reviewer resolving disagreements. Data extraction used a customised Covidence template and only intention-to-treat participants were included in analyses. The internal validity (risk of bias) of included trials was independently assessed and results were stratified by study quality; the quality assessment did not determine whether studies were included. For synthesis the investigators used Review Manager v5.4.1 and a random-effects model to allow for between-study heterogeneity. Outcomes measured on the same scale were combined as mean differences (MD); outcomes on different scales used standardised mean differences (SMD; Hedges' g). Ninety-five percent confidence intervals, two-tailed p-values, Tau-squared and I2 were calculated to quantify heterogeneity, and prediction intervals were computed for MD outcomes. The authors interpreted Hedges' g using conventional thresholds (0.2 small, 0.5 medium, 0.8 large).

Six randomised psychotherapy-alone control comparisons were included, with individual study sample sizes ranging from 8 to 91 middle-aged adults and a pooled n reported for primary outcome analyses of 169. Trials spanned 2011 to 2021 and included one unpublished RCT identified via registries. On the primary outcome of PTSD severity (CAPS), the meta-analysis found a large and statistically significant effect favouring MDMA-AP: Hedges' g = 0.93 (95% CI, 0.60 to 1.25; p < .001), with a prediction interval reported as 0.52 to 1.38. Between-study heterogeneity for this outcome was negligible (Q(5) = 1.87; p = 0.87; tau2 = 0.00; I2 = 0%). Secondary outcomes largely favoured MDMA-AP. Dissociation severity (DES-II) showed a significant mean difference of -9.70 (95% CI, -13.39 to -6.12; p < .001; n = 38) with low heterogeneity (I2 = 7%). Functional impairment demonstrated a large standardised effect (g = 0.82; 95% CI, 0.10 to 1.73; p = 0.03; n = 118) with moderate heterogeneity (I2 = 52%). Comorbid depression decreased significantly (MD = -11.13; 95% CI, -19.35 to -2.92; p = 0.008; n = 137) though heterogeneity was substantial (I2 = 72%). Sleep disturbance did not reach statistical significance at the primary endpoint (MD = -3.67; 95% CI, -7.70 to 0.36; p = 0.07; n = 46; I2 = 65%), though authors note improvements at follow-up. Physiological measures indicated an acute increase in heart rate during treatment sessions (MD = 12.88 bpm; 95% CI, 0.97 to 24.79; p = 0.03; n = 32) with no significant pooled increases reported for diastolic or systolic blood pressure or body temperature; heart rate heterogeneity was low (I2 = 0%). Assessments of confidence in the evidence characterised internal validity of the included studies as moderate to high. Excluding two studies judged high risk of bias produced the same primary outcome effect size (reported as g = 0.93 with a 95% CI presented in the extracted text as 1.27 to 0.58; note: the confidence interval ordering in the extraction appears reversed). Egger's regression for publication bias yielded p = 0.07, and one identified RCT was not journal published.

Green and colleagues interpret their findings as evidence that MDMA-AP produces substantial reductions in clinician-rated PTSD severity within a small number of treatment sessions (typically two to three). They highlight the magnitude of the pooled effect on CAPS and emphasise improvements in secondary domains that matter for patients, including dissociation, depression and daily functioning. The authors note that these multi-domain effects may reflect MDMA's hypothesised facilitation of psychotherapeutic processes such as memory reactivation and reconsolidation, enhanced cognitive flexibility, and facilitated fear extinction. Compared with earlier meta-analyses, the present synthesis incorporates two additional RCTs and an unpublished trial and uses a standardised mean difference approach to accommodate CAPS versions (DSM-IV versus DSM-5). The study team reports consistency of the primary effect after excluding higher risk-of-bias trials and found no clear evidence of publication bias on Egger's test. The authors also draw attention to the temporal profile of benefit, reporting maintenance of PTSD symptom reduction in follow-up periods ranging from one to 3.8 years in the included trials. Safety considerations are discussed with respect to acute cardiovascular effects: pooled analyses showed an average heart rate increase of approximately 13 beats per minute during sessions, which the authors interpret as indicative of sympathetic activation and a potential concern for participants with pre-existing cardiac vulnerability. They state this finding does not, in their view, undermine the treatment's safety in the studied samples but argues for caution in populations with cardiac risk. Limitations acknowledged by the investigators include small pooled sample sizes (with only one Phase III trial large enough to be well powered), the single-sponsor nature of the evidence base (MAPS), and the lack of independent standardisation or replication of the specific nondirective psychotherapeutic approach used in these trials. They point out that MDMA-AP has not been tested head-to-head against established psychotherapies such as cognitive processing therapy, trauma-focused CBT or EMDR, nor directly compared with approved pharmacological treatments, which limits conclusions about comparative effectiveness. The authors call for independent, larger RCTs including active comparator arms and further standardisation of the psychotherapeutic component.

The authors conclude that combining MDMA (reported dosing 120–125 mg) with psychotherapy is very effective in reducing PTSD severity on CAPS and produces significant improvements in associated outcomes including dissociation, depression and functional quality of life; sleep quality may improve but did not reach statistical significance at the primary endpoint. They recommend further independent randomised trials with larger cohorts and direct comparisons to established evidence-based psychotherapies and pharmacological treatments, and they stress the need to identify and evaluate an appropriate evidence-based psychotherapeutic approach to pair with MDMA in future studies.